CASI Net Current Asset Value from 2010 to 2026

CASI Stock  USD 0.92  0.03  3.16%   
CASI Pharmaceuticals' Net Current Asset Value is steady with stable movements from year to year. Net Current Asset Value will most likely to flatten out to 0.00. As of now, CASI Pharmaceuticals' Depreciation And Amortization is increasing as compared to previous years. The CASI Pharmaceuticals' current Research Development is estimated to increase to about 10.7 M, while Interest Expense is projected to decrease to under 794 K. . View All Fundamentals
 
Net Current Asset Value  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
0.0
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check CASI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CASI Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 794 K, Selling General Administrative of 28.5 M or Other Operating Expenses of 82.3 M, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.0092 or PTB Ratio of 28.32. CASI financial statements analysis is a perfect complement when working with CASI Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with CASI Stock
Check out the analysis of CASI Pharmaceuticals Correlation against competitors.
For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

Currently Active Assets on Macroaxis

When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:
Check out the analysis of CASI Pharmaceuticals Correlation against competitors.
For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.02)
Revenue Per Share
1.622
Quarterly Revenue Growth
(0.60)
Return On Assets
(0.62)
Return On Equity
(10.95)
Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.